2 recruiting, 1 not yet recruiting. 1 Not applicable, 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow De-escalation strategy: new trials by email Literature Review of De-escalation strategy trials Research Report on De-escalation strategy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Testing if Patients With Advanced Prostate Cancer Who Are Responding Well to Combination Treatment Can Safely Reduce Their Medication to a Single Hormone Therapy, Compared to Continuing Their Current Drugs De-escalation strategy, Continuation of initial Androgen Deprivation Therapy (ADT) and Androgen Receptor Pathway Inhibitor (ARPI) combination therapy at standard doses - Castration Sensitive Prostate Cancer, Metastatic Prostate Cancer | Phase 2 | Not yet recruiting | Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute | 170 | 2026-09-01 | 2026-10-07 |
| HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer HAIC(GOLF), Bevacizumab, PD-1/PD-L1 inhibitor - Biliary Tract Cancer (BTC) | Not applicable | Recruiting | Peking University | 40 | 2026-03-31 | 2026-05-08 |
| Ticagrelor De-escalation Strategy in AMI Patients De-escalation strategy, Conventional strategy - Acute Myocardial Infarction | Phase 4 | Recruiting | Dong-A University | 2312 | 2023-03-27 | 2025-10-01 |
Biliary Tract Neoplasms (1) · Prostatic Neoplasms (1)
Dong-A University (1) · Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute (1) · Peking University (1)
China (1) · India (1) · South Korea (1)
Moo Hyun Kim, MD, PhD (1) · Xiaodong Wang (1)
PMID 26376600, PMID 28810251, PMID 33032710, PMID 33171520, PMID 33802015, PMID 34622433, PMID 36578832, PMID 37072035, PMID 37474795